key: cord-0990754-h86gvzed
authors: Turcato, Gianni; Zaboli, Arian; Pfeifer, Norbert; Ciccariello, Laura; Sibilio, Serena; Tezza, Giovanna; Ausserhofer, Dietmar
title: Clinical application of a rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic patients evaluated in the emergency department: a preliminary report.
date: 2020-12-19
journal: J Infect
DOI: 10.1016/j.jinf.2020.12.012
sha: 6dddf9a659d988b6790080a518df3d827f5fbdb6
doc_id: 990754
cord_uid: h86gvzed

nan

LETTER TO THE EDITOR Title: Clinical application of a rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic patients evaluated in the emergency department: a preliminary report.

Gianni Turcato, MD * , Arian Zaboli, RN In their article "Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2:

A diagnostic accuracy study", Azzi and colleagues reported on the validity of rapid antigen tests (RATs) performed on salivary samples from 119 patients [1] . Comparing the results of RATs to those of reverse transcription polymerase chain reaction (RT-PCR)-based tests for viral RNA, the sensitivity was high (0.93, 95% CI: 0.77-0.99), while the specificity was low (0.42, 95% CI: 0.32-0.53). In their study, no differences were observed between subgroups or between asymptomatic and symptomatic individuals [1] . We agree with the authors that RATs could be a valuable tool in mass screening strategies, especially to control the pandemic during the reopening period.

We propose that a similar strategy be adapted to emergency departments (EDs), in which the rapid and accurate identification of SARS-CoV-2-infected patients is crucial, especially in a phase of reduced prevalence of infections in the population [2] . In addition to the rapid identification of SARS-CoV-2-infected patients admitted with COVID-19-like symptoms, it is also crucial for the ED to accurately identify patients with other symptoms who may be asymptomatic carriers of SARS-CoV-2 and who, if not promptly identified, could spread the infection within the hospital [2, 3, 4] . The RT-PCR test for viral RNA is the gold-standard diagnostic for SARS-CoV-2 infection, yet the results are often delayed and are thus not immediately available for every patient. This is not suitable for the ED timing. Due to their quick execution and the timeliness of their results, RATs could overcome the limitations of RT-PCR testing and improve the risk management of infection and transmission in the ED [2, 5] . Initial validation studies of RATs were conducted in small laboratory cohorts with a high prevalence of infection [2, 5, 6, 7] . Clinical data on RATs in the ED setting that include symptomatic and asymptomatic patients with a disease prevalence similar to the general population (<10%) are still not available [7] . Thus, we would like to take the opportunity to report preliminary findings from our observational study on the implementation of RATs in the initial screening of patients arriving in the ED for either COVID-like symptoms or other health issues. In addition to the assessment of the diagnostic accuracy of the RAT, a preliminary broader evaluation on the possible global clinical benefit derived from the use of RATs as an initial screening tool in the ED was performed via decision curve analysis (DCA). The DCA plot confirm that when the prevalence of infection in the general population is under 15% (similar to real data, in contrast to the validation laboratory cohorts), initial screening with RAT in the ED has a nonnegligible net clinical benefit (Figure 1 ).

Our preliminary findings on the diagnostic performance of RAT in clinical practice are in line with those previously observed in laboratory studies. In contrast to previous studies, in which the prevalence of COVID-19 in the study samples was high, the current study reports a prevalence that more closely reflects the true prevalence of infection in the general population [5, 6, 7] . In symptomatic patients, the performance of the RAT seems to be high enough to propose its use as an initial screening test directly upon arrival in triage [7] . In these patients, a positive RAT may accelerate the management of the infected patient, while in case of a negative test, the subsequent clinical management may depend on the degree of clinical suspicion. In asymptomatic patients, in whom RATs do not currently appear sufficient to properly identify the infected patients, a positive test may nonetheless identify patients who otherwise, without clinical suspicion, would not have been detected. However, a negative RAT in patients with low clinical suspicion cannot completely exclude the presence of SARS-CoV-2 infection.

Their immediate availability for each patient, the easy repeatability and the rapidity of the result are characteristics that make the RAT appealing for mass screening or for environments, such as the ED, in which rapid information is crucial. The introduction of a rapid screening tool for both symptomatic and asymptomatic patients upon arrival in the ED appears to improve the overall management of the infectious risk, with a net clinical benefit.

In conclusion, the use of a RAT implemented for infectious risk assessment directly in triage should be considered in EDs and could be an additional tool to address the challenge of containing the SARS-CoV-2 pandemic. 

Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic accuracy study

Containing COVID-19 in the Emergency Department: The Role of Improved Case Detection and Segregation of Suspect Cases

Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'

COVID-19 transmission through asymptomatic carriers is a challenge to containment. Influenza Other Respir Viruses

Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples

Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients

Van den Bruel A. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection